Replies to post #250079 on Biotech Values

[DewDiligence]

AADI addendum—The probability that a single-agent cancer drug has a clinically meaningful benefit in overall survival is very low when the ORR is as low as the numbers observed in AADI’s trial:

https://www.sciencedirect.com/science/article/pii/S2213538323000796

AADI is down 57% as I’m typing.